Literature DB >> 10482919

Action of AT1 receptor antagonists on angiotensin II-induced tone in human isolated subcutaneous resistance arteries.

R S Garcha1, P S Sever, A D Hughes.   

Abstract

1. Human isolated subcutaneous arteries were studied under isometric conditions in a myograph. 2. Addition of angiotensin II (AII) induced a concentration-dependent increase in tone in isolated arteries. The active metabolite of candesartan (CV 11974), losartan and the active metabolite of losartan, E-3174 antagonized AII-induced tone in a non-competitive manner, but the AT2 selective antagonist, PD123319, was without effect on responses to AII. The effects of candesartan, losartan and E-3174 were analysed using a classical model of non-competitive antagonism and a two-state receptor model. 3. Mechanical removal of the endothelium; pre-incubation with Nomega-nitro-L-arginine methyl ester hydrochloride (L-NAME); pre-incubation with indomethacin, a cyclo-oxygenase inhibitor; or pre-incubation with BQ 485, an endothelin antagonist; had no significant effect on contractions induced by AII. 4. Our results suggest AII contracts human isolated resistance arteries by an action on AT1 receptors and does not involve release of endothelial factors. Use of a two-state receptor model successfully described the action of the AT1 antagonists without sacrificing assumptions regarding the competitive nature of binding of these antagonists.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10482919      PMCID: PMC1566168          DOI: 10.1038/sj.bjp.0702722

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  47 in total

1.  Nonpeptide angiotensin II receptor antagonists. XI. Pharmacology of EXP3174: an active metabolite of DuP 753, an orally active antihypertensive agent.

Authors:  P C Wong; W A Price; A T Chiu; J V Duncia; D J Carini; R R Wexler; A L Johnson; P B Timmermans
Journal:  J Pharmacol Exp Ther       Date:  1990-10       Impact factor: 4.030

2.  [3H]DUP 753, a highly potent and specific radioligand for the angiotensin II-1 receptor subtype.

Authors:  A T Chiu; D E McCall; P E Aldrich; P B Timmermans
Journal:  Biochem Biophys Res Commun       Date:  1990-11-15       Impact factor: 3.575

3.  Endothelium-dependent contractions induced by angiotensin I and angiotensin II in canine cerebral artery.

Authors:  K Manabe; H Shirahase; H Usui; K Kurahashi; M Fujiwara
Journal:  J Pharmacol Exp Ther       Date:  1989-10       Impact factor: 4.030

4.  On the mechanism of desensitization at cholinergic receptors.

Authors:  H P Rang; J M Ritter
Journal:  Mol Pharmacol       Date:  1970-07       Impact factor: 4.436

5.  Nitric oxide and angiotensin II. Glomerular and tubular interaction in the rat.

Authors:  L De Nicola; R C Blantz; F B Gabbai
Journal:  J Clin Invest       Date:  1992-04       Impact factor: 14.808

6.  Alterations of cyclo-oxygenase products and NO in responses to angiotensin II of resistance arteries from the spontaneously hypertensive rat.

Authors:  S F Côrtes; R Andriantsitohaina; J C Stoclet
Journal:  Br J Pharmacol       Date:  1996-12       Impact factor: 8.739

7.  [Angiotensin II stimulates endothelin-1 release from human endothelial cells].

Authors:  S A Ciafré; F P D'Armiento; F Di Gregorio; P Colasanti; A Di Benedetto; A Langella; N Di Ieso; A Liguori; R Colasanti; C Napoli
Journal:  Recenti Prog Med       Date:  1993-04

8.  Influence of the vascular endothelium on angiotensin II-induced contractions in rabbit renal artery.

Authors:  J Zhang; M Pfaffendorf; J S Zhang; P A van Zwieten
Journal:  Fundam Clin Pharmacol       Date:  1995       Impact factor: 2.748

9.  Characterization of arginine vasopressin actions in human uterine artery: lack of role of the vascular endothelium.

Authors:  A Jovanović; L Grbović; I Zikić; I Tulic
Journal:  Br J Pharmacol       Date:  1995-08       Impact factor: 8.739

View more
  1 in total

1.  Mechanism of action of angiotensin II in human isolated subcutaneous resistance arteries.

Authors:  R S Garcha; P S Sever; A D Hughes
Journal:  Br J Pharmacol       Date:  2001-09       Impact factor: 8.739

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.